Sarcomatrix Therapeutics Launches SarcoVista™ AI Platform as Lead Candidate S-969 Advances Toward First-in-Human Studies
Platform leverages muscle biology to de-risk development and identify new therapeutic targets ahead of clinical entry RENO, NV, UNITED STATES, March 31, 2026 /EINPresswire.com/ -- Sarcomatrix Therapeutics (“Sarcomatrix” or the “Company”), a …